Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00650871 |
A study to investigate the effects of GW679769 on sleep and cognition. Potential subjects participate in a clinical screening visit and a two-night PSG recording session in the sleep laboratory. Eligible subjects then participate in three separate two-night PSG sessions in which they are randomized to receive placebo or one of two doses of GW679769 60 minutes prior to bedtime, one treatment for each session in a balanced order. Each treatment session is separated by a two-week drug-free period and occur on the same day of the week. A safety follow-up visit occurs 2 weeks after the last treatment session.
Condition | Intervention | Phase |
---|---|---|
Insomnia |
Drug: GW679769 Drug: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Diagnostic, Randomized, Double-Blind, Crossover Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effects of GW679769 (30mg and 90mg) on Sleep Continuity, PSG Sleep Recordings, Subjective Sleep Assessment, and Daytime Cognitive Function in Subjects With Primary Insomnia |
Enrollment: | 48 |
Study Start Date: | July 2004 |
Study Completion Date: | August 2005 |
Primary Completion Date: | August 2005 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years to 64 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
GSK Investigational Site | |
San Diego, California, United States, 92123 | |
United States, Georgia | |
GSK Investigational Site | |
Atlanta, Georgia, United States, 30342 | |
United States, New York | |
GSK Investigational Site | |
New York, New York, United States, 10025 | |
United States, North Carolina | |
GSK Investigational Site | |
Winston-Salem, North Carolina, United States, 27157 | |
GSK Investigational Site | |
Durham, North Carolina, United States | |
United States, Ohio | |
GSK Investigational Site | |
Cincinnati, Ohio, United States, 45246 | |
United States, Pennsylvania | |
GSK Investigational Site | |
Philadelphia, Pennsylvania, United States, 19107 |
Study Director: | GSK Clinical Trials, MD | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | GW679769/903 |
Study First Received: | March 31, 2008 |
Last Updated: | November 18, 2008 |
ClinicalTrials.gov Identifier: | NCT00650871 |
Health Authority: | United States: Food and Drug Administration; United States: Food and Drug Administration |
GW679769, sleep, cognitive function, primary insomnia, polysomnography. |
Sleep Initiation and Maintenance Disorders Mental Disorders Dyssomnias Sleep Disorders Sleep Disorders, Intrinsic |
Nervous System Diseases |